Evidence supporting the association between pCR and survival benefit has been previously demonstrated, especially for aggressive tumors such as triple-negative breast cancer (TNBC) and hormone receptor-negative/HER2-positive (HR−/HER2+) cancer [3–6]. This evidence concerns the gene ERBB2 and cancer.